The humanized monoclonal antibody Eculizumab in contrast to the complement component 5 (C5) has shown beneficial effects of STEC-associated HUS rehabilitation including clinical trials (Grisaru, 2014; Mahat et al., 2019). Here, C5 is linked to hemolytic-uremic syndrome.